Lv1
40 积分 2025-05-15 加入
1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib
1天前
已完结
The Role of Rapamycin in Healthspan Extension via the Delay of Organ Aging
1个月前
已完结
Cancer will cost the world $25 trillion over next 30 years
1个月前
已完结
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
1个月前
已完结
The global burden of lung cancer: current status and future trends
1个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
1个月前
已完结
206 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
2个月前
已完结
Investigating the impact of trial retractions on the healthcare evidence ecosystem (VITALITY Study I): retrospective cohort study
2个月前
已完结
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
2个月前
已完结
LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
2个月前
已完结
皖公网安备34019202002308
